Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNRHR | P30968 | 16/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 10/20 | 0.44 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30178539 | 0.91 | GNRHR (0.45) | GNRHRCYP3A4MEN1KMT2A | |
| SCHEMBL19873767 | 0.91 | GNRHR (0.45) | GNRHRCYP3A4MEN1KMT2A | |
| SCHEMBL19873682 | 0.88 | GNRHR (0.44) | GNRHRCYP3A4 | |
| SCHEMBL30178392 | 0.88 | GNRHR (0.44) | GNRHRCYP3A4 | |
| SCHEMBL17870829 | 0.88 | GNRHR (0.42) | GNRHRCYP3A4MEN1KMT2A | |
| SCHEMBL30178400 | 0.88 | GNRHR (0.42) | GNRHRCYP3A4MEN1KMT2A | |
| SCHEMBL30178420 | 0.87 | GNRHR (0.43) | GNRHRCYP3A4 | |
| SCHEMBL19873676 | 0.87 | GNRHR (0.43) | GNRHRCYP3A4 | |
| SCHEMBL30178503 | 0.87 | GNRHR (0.40) | GNRHRCYP3A4MEN1KMT2A | |
| SCHEMBL17870804 | 0.86 | GNRHR (0.41) | GNRHRCYP3A4MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107428744-B | Novel heterocyclic compounds and their use in medicine and cosmetics | 盖尔德马研究及发展公司 | 2021-09-24 | — | — | CN | disclosed |
| US-10246422-B2 | Heterocyclic compounds and use thereof in medicine and in cosmetics | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2019-04-02 | — | — | US | disclosed |
| US-20180050992-A1 | NOVEL HETEROCYCLIC COMPOUNDS AND USE THEREOF IN MEDICINE AND IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2018-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180050992-A1 | NOVEL HETEROCYCLIC COMPOUNDS AND USE THEREOF IN MEDICINE AND IN COSMETICS | MC1R, CALCRL, BDKRB2 | GNRHR 215/4885CYP3A4 2314/4885ADORA2B 346/4885 |
| US-10246422-B2 | Heterocyclic compounds and use thereof in medicine and in cosmetics | MC1R, BDKRB2, CCKBR | GNRHR 201/4885CYP3A4 1806/4885ADORA2B 326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.